Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice - PubMed (original) (raw)
. 1994 Dec;35(12):2263-7.
Affiliations
- PMID: 7897323
Free article
Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice
A C Liu et al. J Lipid Res. 1994 Dec.
Free article
Abstract
Elevated levels of apolipoprotein[a] (apo[a]) and apolipoprotein A-I (apoA-I) are associated, respectively, with increased and decreased atherosclerosis risk, in both humans and transgenic mice. To investigate the interactions of these two important lipid-associated proteins, we assessed the effect of expression of human apoA-I and apo[a] transgenes, both singularly and together, on murine atherogenesis. Mice expressing the apo[a] transgene have a lipoprotein profile similar to nontransgenic controls, yet have significantly increased susceptibility to diet-induced atherosclerosis. Compared to mice expressing only the apo[a] transgene, mice expressing both apo[a] and apoA-I transgenes have twofold greater high density lipoprotein (HDL) concentrations and approximately a 20-fold decrease in development of early atherosclerotic lesions. The finding of decreased atherosclerosis in the setting of elevated apo[a] and apoA-I suggests that elevations of apoA-I and HDL have a dominant effect in reducing atherosclerosis susceptibility in various settings, including those not associated with alterations of plasma lipids.
Similar articles
- Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis.
Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, Najib J, Fruchart JC, Miller NE, Zakin MM, Ochoa A. Vergnes L, et al. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2267-74. doi: 10.1161/01.atv.20.10.2267. Arterioscler Thromb Vasc Biol. 2000. PMID: 11031214 - Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).
Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V, Hammer RE, Hobbs HH. Sanan DA, et al. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4544-9. doi: 10.1073/pnas.95.8.4544. Proc Natl Acad Sci U S A. 1998. PMID: 9539774 Free PMC article. - Protection against atherogenesis in mice mediated by human apolipoprotein A-IV.
Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denèfle P. Duverger N, et al. Science. 1996 Aug 16;273(5277):966-8. doi: 10.1126/science.273.5277.966. Science. 1996. PMID: 8688083 - The apolipoprotein(a) gene: characterization of 5' flanking regions and expression in transgenic mice.
Lawn RM. Lawn RM. Chem Phys Lipids. 1994 Jan;67-68:19-23. doi: 10.1016/0009-3084(94)90120-1. Chem Phys Lipids. 1994. PMID: 8187213 Review. - Apolipoprotein A-II, HDL metabolism and atherosclerosis.
Tailleux A, Duriez P, Fruchart JC, Clavey V. Tailleux A, et al. Atherosclerosis. 2002 Sep;164(1):1-13. doi: 10.1016/s0021-9150(01)00751-1. Atherosclerosis. 2002. PMID: 12119188 Review.
Cited by
- Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.
Kothari V, Ho TWW, Cabodevilla AG, He Y, Kramer F, Shimizu-Albergine M, Kanter JE, Snell-Bergeon J, Fisher EA, Shao B, Heinecke JW, Wobbrock JO, Lee WL, Goldberg IJ, Vaisar T, Bornfeldt KE. Kothari V, et al. Circ Res. 2024 Jul 5;135(2):335-349. doi: 10.1161/CIRCRESAHA.123.323100. Epub 2024 Jun 3. Circ Res. 2024. PMID: 38828596 Free PMC article. - High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review.
Zhen J, Li X, Yu H, Du B. Zhen J, et al. J Nanobiotechnology. 2024 May 17;22(1):263. doi: 10.1186/s12951-024-02529-x. J Nanobiotechnology. 2024. PMID: 38760755 Free PMC article. Review. - A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease.
Rani A, Marsche G. Rani A, et al. Pharmaceutics. 2023 May 15;15(5):1504. doi: 10.3390/pharmaceutics15051504. Pharmaceutics. 2023. PMID: 37242746 Free PMC article. Review. - Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis.
Li Y, Xu Y, Jadhav K, Zhu Y, Yin L, Zhang Y. Li Y, et al. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1574-1587. doi: 10.1161/ATVBAHA.119.312610. Epub 2019 Jul 11. Arterioscler Thromb Vasc Biol. 2019. PMID: 31291759 Free PMC article. - Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice.
Méndez-Lara KA, Farré N, Santos D, Rivas-Urbina A, Metso J, Sánchez-Quesada JL, Llorente-Cortes V, Errico TL, Lerma E, Jauhiainen M, Martín-Campos JM, Alonso N, Escolà-Gil JC, Blanco-Vaca F, Julve J. Méndez-Lara KA, et al. Int J Mol Sci. 2019 Feb 2;20(3):655. doi: 10.3390/ijms20030655. Int J Mol Sci. 2019. PMID: 30717414 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources